+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

OutSmarting Osteosarcoma Hero Award

MIB Agents

The 2026 LOI submission period is now closed. Approved LOIs will be notified in early December and invited to submit a full application by January 25, 2026.
‍
The OutSmarting Osteosarcoma Hero Award
$100,000 grant over one year to investigators with a compelling study that will Make It Better for osteosarcoma patients.

FUNDING PRIORITIES

To have the most immediate impact on patient care and outcomes, MIB Agents funding priorities are:

● Late-stage translational research - research may lead to clinical benefit or a clinical trial in less than five years.

● Studies with promising preclinical data that have a specific funding need to secure an IND and move forward to a clinical trial.

● Specific funding gaps in clinical research. Examples include correlative studies associated with and/or before an already funded clinical trial.

● Projects that facilitate and enhance collaboration and shared learnings.

AI Based Application Success Predictor

1. Absolute, Explicit Focus on Osteosarcoma

MIB Agents exclusively funds projects that directly improve outcomes for osteosarcoma patients.

High-priority topics include:

New therapeutic targets for osteosarcoma

Drug repurposing or combination strategies

Mechanisms of metastasis (especially lung metastasis)

Chemoresistance biology

Immunotherapy for osteosarcoma

Biomarkers or liquid biopsy

Better preclinical models (PDX, organoids, canine OS)

Novel radiology/imaging approaches

Survivorship, quality of life, and late toxicity in OS

❗ Generic sarcoma or bone cancer projects are not competitive unless they clearly center on osteosarcoma.

2. Fit With MIB Agents’ Grant Mechanisms

MIB Agents has several funding mechanisms with different expectations:

🔹 OutSmarting Osteosarcoma Grant (Flagship Award)

Early/mid-career investigators

Strong scientific rigor + translational potential

Must meaningfully address OS treatment, biology, or detection

High innovation strongly preferred

🔹 FACTORY Grants (Fast-Track, High-Impact)

Rapid, short-term projects

Emphasis on feasibility + clear deliverables

Often used for validating targets or methods quickly

🔹 Junior Investigator or Fellow Awards

Early-career focus

Strong mentorship required

🔹 Clinical/Translational Grants

Access to patients, tissue, trial infrastructure

Must have near-term clinical applicability

Predictor: Align your career stage, scope, and deliverables to the exact MIB mechanism.

3. High Translational Relevance

MIB Agents emphasizes applied research that will make a near-term difference.

Competitive proposals typically show:

Direct therapeutic development

Mechanistic discovery that leads to testable intervention

Biomarkers that can move into clinical settings

Strategies to reduce toxicity or improve quality of life

Work that accelerates drug development pipelines

Predictor: Proposals must clearly articulate how the project will improve survival or care for osteosarcoma patients.

4. Strong Preliminary Data

Even small or pilot grants usually require evidence of feasibility:

Early mechanistic data

Drug-response assays

Pilot biomarker results

Feasibility of obtaining samples

Early animal or in vitro model proof-of-concept

Predictor: Preliminary data is one of the strongest determinants of success.

5. Use of Osteosarcoma-Relevant Models

Highly successful proposals use validated osteosarcoma systems:

Patient-derived xenografts (PDX)

OS organoids or 3D culture

CRISPR or engineered OS cell line models

Canine osteosarcoma models (strongly valued due to translational relevance)

Lung metastasis models

Longitudinal imaging or ctDNA assays

Predictor: The use of state-of-the-art OS models greatly increases translational usefulness.

6. Collaboration & Data Sharing

MIB Agents strongly values collaborative science:

Multi-PI approaches

Clinician + basic scientist teams

Data sharing among OS groups

Partnerships with Children’s Oncology Group (COG), NCI, or other sarcoma consortia

Cross-institutional resource sharing

Predictor: Collaborative, synergistic proposals score significantly higher.

7. Patient-Centered Design

MIB Agents is a patient-driven organization, so proposals are strengthened by:

Clear relevance to patient outcomes (survival, QoL, toxicity reduction)

Inclusion of patient advocates where possible

Real-world justification for the proposed approach

Predictor: Projects that directly reflect patient needs have an advantage.

8. Strong Investigator Potential and Expertise

Reviewers look for:

Evidence of commitment to osteosarcoma research

Relevant publications in OS or bone/solid tumor models

Grantsmanship potential and clear research trajectory

Technical capability to carry out the project

Predictor: Investigator expertise in OS (or a compelling mentorship structure) increases reviewer confidence.

9. Clear, Focused, Milestone-Based Specific Aims

Successful proposals have:

2–3 well-defined aims

Measurable milestones

Realistic timelines

Clear go/no-go points

Strong contingency plans

Predictor: MIB Agents prioritizes feasibility + fast impact, so well-structured aims perform well.

10. Strong, Clean Writing and Visuals

Top-scoring grants are:

Exceptionally clear

Logically structured

Supported by strong visual preliminary data

Easy for both scientists and clinicians to understand

Predictor: High-quality communication significantly increases competitiveness.

🏆 Summary Table – MIB Agents Funding Predictors

Predictor	Why It Matters
Osteosarcoma-specific focus	Core requirement
Mechanism fit	Ensures proper expectations
Translational potential	MIB is impact-driven
Preliminary data	Demonstrates feasibility
Relevant OS models	Strengthens translational value
Collaboration	High priority for OS research
Patient-centered impact	Aligns with MIB’s mission
PI track record	Supports likelihood of success
Focused, feasible aims	Required for short-term grants
Strong writing & visuals	Improves reviewer enthusiasm

Specialties

Clinical Trials

General Medicine

Eligibility Requirements

● The principal investigator (PI) must be an independent investigator with experience in translational research.

● Academic ranks of Assistant Professor, Associate Professor, Professor, and research scientists with M.D., D.O., D.V.M., and/or Ph.D. degrees may apply.

Sponsor Details

Sponsor Institute/Organizations: MIB Agents

Sponsor Type: Corporate/Non-Profit

Address: P.O. Box 858, Barnard, VT 05031 518.524.3890 hello@MIBagents.org

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity